"Proto-Oncogene Proteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity.
| Descriptor ID |
D011518
|
| MeSH Number(s) |
D12.776.624.664.700
|
| Concept/Terms |
Proto-Oncogene Proteins- Proto-Oncogene Proteins
- Proto Oncogene Proteins
- Proto-Oncogene Products, Cellular
- Cellular Proto-Oncogene Products
- Proto Oncogene Products, Cellular
- Proto Oncogene Proteins, Cellular
- c-onc Proteins
- c onc Proteins
- Cellular Proto-Oncogene Proteins
- Cellular Proto Oncogene Proteins
- Proto-Oncogene Proteins, Cellular
|
Below are MeSH descriptors whose meaning is more general than "Proto-Oncogene Proteins".
Below are MeSH descriptors whose meaning is more specific than "Proto-Oncogene Proteins".
This graph shows the total number of publications written about "Proto-Oncogene Proteins" by people in this website by year, and whether "Proto-Oncogene Proteins" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 11 | 4 | 15 |
| 1995 | 14 | 6 | 20 |
| 1996 | 11 | 4 | 15 |
| 1997 | 11 | 9 | 20 |
| 1998 | 5 | 3 | 8 |
| 1999 | 7 | 6 | 13 |
| 2000 | 8 | 8 | 16 |
| 2001 | 8 | 11 | 19 |
| 2002 | 19 | 19 | 38 |
| 2003 | 13 | 17 | 30 |
| 2004 | 24 | 11 | 35 |
| 2005 | 6 | 6 | 12 |
| 2006 | 3 | 6 | 9 |
| 2007 | 7 | 2 | 9 |
| 2008 | 6 | 6 | 12 |
| 2009 | 9 | 2 | 11 |
| 2010 | 11 | 13 | 24 |
| 2011 | 9 | 6 | 15 |
| 2012 | 13 | 10 | 23 |
| 2013 | 12 | 8 | 20 |
| 2014 | 16 | 6 | 22 |
| 2015 | 19 | 2 | 21 |
| 2016 | 4 | 6 | 10 |
| 2017 | 3 | 3 | 6 |
| 2018 | 6 | 7 | 13 |
| 2019 | 8 | 2 | 10 |
| 2020 | 5 | 2 | 7 |
| 2021 | 6 | 6 | 12 |
| 2022 | 4 | 3 | 7 |
| 2023 | 2 | 4 | 6 |
| 2024 | 4 | 0 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Proto-Oncogene Proteins" by people in Profiles.
-
MEN1/DAXX/ATRX mutations enhance progression-free survival in gastroenteropancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy. Endocr Relat Cancer. 2024 Nov 01; 31(11).
-
Aberrant activation of AXL may drive progression of squamous cell carcinoma in CLL patients: a mechanistic study with clinical implications. Br J Cancer. 2024 Aug; 131(3):589-600.
-
Investigation of inherited noncoding genetic variation impacting the pharmacogenomics of childhood acute lymphoblastic leukemia treatment. Nat Commun. 2024 May 01; 15(1):3681.
-
PU.1 and BCL11B sequentially cooperate with RUNX1 to anchor mSWI/SNF to poise the T cell effector landscape. Nat Immunol. 2024 May; 25(5):860-872.
-
Single-nucleus DNA sequencing reveals hidden somatic loss-of-heterozygosity in Cerebral Cavernous Malformations. Nat Commun. 2023 11 02; 14(1):7009.
-
Concurrent high-grade glioma with cavernous malformations and pathogenic variants in PDCD10 and SMARCA4. Childs Nerv Syst. 2023 11; 39(11):3311-3315.
-
Ratiometric sensing of Pnt and Yan transcription factor levels confers ultrasensitivity to photoreceptor fate transitions in Drosophila. Development. 2023 04 15; 150(8).
-
Dual Axl/MerTK inhibitor INCB081776 creates a proinflammatory tumor immune microenvironment and enhances anti-PDL1 efficacy in head and neck cancer. Head Neck. 2023 05; 45(5):1255-1271.
-
The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia. Nature. 2023 03; 615(7954):920-924.
-
TET1 and TDG Suppress Inflammatory Response in Intestinal Tumorigenesis: Implications for Colorectal Tumors With the CpG Island Methylator Phenotype. Gastroenterology. 2023 05; 164(6):921-936.e1.